Chr. Hansen: Lonza joint venture wins antitrust approval
(CercleFinance.com) - Antitrust regulators have granted Denmark's Chr.
Hansen and Switzerland's Lonza approval for a joint venture on the market of live biotherapeutic products.
The companies said they have received the relevant approvals needed to establish their 50/50 joint venture, which was originally announced in April.
Basel-based BacThera - which will offer manufacturing of bacteria strains for therapeutic use - is now engaging with its first biotech and pharma customers, the groups said.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
Hansen and Switzerland's Lonza approval for a joint venture on the market of live biotherapeutic products.
The companies said they have received the relevant approvals needed to establish their 50/50 joint venture, which was originally announced in April.
Basel-based BacThera - which will offer manufacturing of bacteria strains for therapeutic use - is now engaging with its first biotech and pharma customers, the groups said.
Copyright (c) 2019 CercleFinance.com. All rights reserved.